Abstract
Immunogenicity/antibody responses are major issues for parenteral proteins and nanotherapeutics (nanovectors, diagnostics, theranostics, etc.), and robust antibody responses require T-helper epitopes. T-helper epitopes consist of specific amino acids at specific positions (anchor positions) in immunogens which contact the major histocompatibility complex (MHC), provide most of the energy for MHC binding and constitute the binding motif for the corresponding MHC alleles. We developed an algorithm that considers motifs to design vaccines lacking unwanted T-cell epitopes, and found numbers of such vaccines can be astronomical (Lee et al. 2009). The algorithm can be used to design reduced immunogenicity proteins, and numbers of predicted proteins are also immense. Reducing T-helper epitope content reduces protein immunogenicity, but the depth of mutagensis needed to eliminate immunogenicity is commonly assumed to be too great for retention of protein bioactivity. However, very deep, but successful substitution, insertion and deletion mutagenesis have been reported. These reports and design space the algorithm reveals suggest development of non-immunogenic therapeutics might be more feasible than commonly assumed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S. Akanuma, T. Kigawa, S. Yokoyama, Combinatorial mutagenesis to restrict amino acid usage in an enzyme to a reduced set. Proc. Natl Acad. Sci. USA 99(21), 13549–53 (2002)
K.D. Bhalerao et al., Nanodevice design through the functional abstraction of biological macromolecules. App. Phys. Lett. 87, 14587–14590 (2005)
B.C. Braden et al., X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). Proc. Natl Acad. Sci. USA 97(22), 12193–7 (2000)
B.M. Brown, R.T. Sauer, Tolerance of Arc repressor to multiple-alanine substitutions. Proc. Natl Acad. Sci. USA 96(5), 1983–8 (1999)
B.-X. Chen et al., Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc. Natl Acad. Sci. USA 95, 10809–10813 (1998)
A. Chirino, M. Ary, S. Marshall, Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 9, 82–90 (2004)
B.C. Cunningham, J.A. Wells, Minimized proteins. Curr. Opin. Struct. Biol. 7(4), 457–62 (1997)
P. Debbage, Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des. 15(2), 153–72 (2009)
P. Debbage, W. Jaschke, Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem. Cell Biol. 130(5), 845–75 (2008)
R.J. Fox, G.W. Huisman, Enzyme optimization: moving from blind evolution to statistical exploration of sequence-function space. Trends Biotechnol. 26(3), 132–8 (2008)
B.K. Klein et al., Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties. Exp. Hematol. 27(12), 1746–56 (1999)
E. Koren, L.A. Zuckerman, A.R. Mire-Sluis, Immune responses to therapeutic proteins in humans–clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3(4), 349–60 (2002)
Y. Kuroda, P.S. Kim, Folding of bovine pancreatic trypsin inhibitor (BPTI) variants in which almost half the residues are alanine. J. Mol. Biol. 298(3), 493–501 (2000)
S.C. Lee et al., Recognition properties of antibodies to PAMAM dendrimers and their use in immune detection of dendrimers. Biomed. Microdevices: Biomems and Biomedical Nanotechnology 3, 51–57 (2001a)
S.C. Lee et al., Phage display mutagenesis of the chimeric dual cytokine receptor agonist myelopoietin. Leukemia 15, 1277–1285 (2001b)
S.C. Lee et al., Biochemical and immunological properties of cytokines conjugated to dendritic polymers. Biomed Microdevices 6(3), 191–202 (2004a)
S.C. Lee, K. Bhalerao, M. Ferrari, Object oriented design tools for supramolecular devices and biomedical nanotechnology. N.Y. Acad. Sci. 1013, 1–14 (2004b)
S. Lee, M. Reugsegger, P.D. Barnes, B.R. Smith, M. Ferrari, Therapeutic nanodevices. Springer Handbook of Nanotechnology, 2nd Edn (2007) p. 461–504
Y. Lee, G. Ferrari, S.C. Lee, Estimating design space avaialable for polyepitopes through consideration of major histocompatibility compmplex binding motifs. Biomedical microdevices, (2009) doi:10.1007/s10544-009-9376-7
C. Mateo et al., Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 19(6), 463–71 (2000)
A. Nijdam, T. Nicholson III, J.P. Shapiro, B.R. Smith, J.T. Heverhagen, P. Schmalbrock, M.V. Knopp, A. Kebbel, D. Wang, S.C. Lee, Nanoparticulate iron oxide contrast agents for untargeted and targeted Cardiovascular magnetic resonance imaging. Curr. Nanosci. 5, 88–102 (2009)
P.O. Olins et al., Saturation mutagenesis of human interleukin-3. J. Biol. Chem. 270(40), 23754–60 (1995)
M. Onda, Reducing the immunogenicity of protein therapeutics. Curr. Drug Targets 10(2), 131–9 (2009)
D.S. Riddle et al., Functional rapidly folding proteins from simplified amino acid sequences. Nat. Struct. Biol. 4(10), 805–9 (1997)
L. Roque-Navarro et al., Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 22(4), 245–57 (2003)
S.A. Ross, P.R. Srinivas, A.J. Clifford, S.C. Lee, M.A. Philbert, R.L. Hetich, New technologies for nutrition research. J. Nutr. 134, 681–685 (2004)
J.H. Sakamoto, B.R. Smith, B. Xie, S.I. Rokhlin, S.C. Lee, M. Ferrari, The molecular analysis of breast cancer utilizing targeted nanoparticle ultrasound contrast agents. Tech. Canc. Res. Treat. 4, 627–636 (2005)
H. Schellekens, Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24(11), 1720–1740 (2002). discussion 1719
D. Shortle, J. Sondek, The emerging role of insertions and deletions in protein engineering. Curr. Opin. Biotechnol. 6(4), 387–93 (1995)
B.R. Smith, J. Heverhagen, M. Knopp, P. Schmalbrock, J. Shapiro, M. Shiomi, N. Moldovan, M. Ferrari, S.C. Lee, Magnetic Resonance Imaging of atherosclerosis in vivo using biochemically targeted ultrasmall superparamagnetic iron oxide particles (SPIONs). Biomed. Microdevices 9, 719–728 (2007)
J. Sondek, D. Shortle, Accommodation of single amino acid insertions by the native state of staphylococcal nuclease. Proteins 7(4), 299–305 (1990)
J. Sondek, D. Shortle, A general strategy for random insertion and substitution mutagenesis: substoichiometric coupling of trinucleotide phosphoramidites. Proc. Natl Acad. Sci. USA 89(8), 3581–5 (1992a)
J. Sondek, D. Shortle, Structural and energetic differences between insertions and substitutions in staphylococcal nuclease. Proteins 13(2), 132–40 (1992b)
S. Tangri et al., Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr. Med. Chem. 9(24), 2191–9 (2002)
S. Tangri et al., Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174(6), 3187–96 (2005)
N.J. Turner, Directed evolution drives the next generation of biocatalysts. Nat. Chem. Biol. 5(8), 567–73 (2009)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, S.C. Implications of available design space for identification of non-immunogenic protein therapeutics. Biomed Microdevices 12, 283–286 (2010). https://doi.org/10.1007/s10544-009-9383-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10544-009-9383-8